Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12

Benzinga · 1d ago
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.